Atara Biotherapeutics Inc Cash Flow Conversion Efficiency
Atara Biotherapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Atara Biotherapeutics Inc (ATRA) has a cash flow conversion efficiency ratio of 0.267x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.79 Million) by net assets ($-36.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Atara Biotherapeutics Inc (2012–2024)
Cash flow conversion efficiency of Atara Biotherapeutics Inc from 2012 to 2024. This chart illustrates how Atara Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ATRA share price today for real-time trading data and today's change.
Atara Biotherapeutics Inc Cash Flow Conversion Ratio Explained
Atara Biotherapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Atara Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atara Biotherapeutics Inc ranked by their cash flow conversion efficiency. Also see ATRA stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Haesung Optics Co. Ltd
KQ:076610
|
-0.009x |
|
Tolins Tyres Ltd
NSE:TOLINS
|
N/A |
|
Sunfar Computer Co Ltd
TWO:6154
|
-0.006x |
|
Advanced Braking Technology Ltd
AU:ABV
|
0.134x |
|
Aldeyra The
NASDAQ:ALDX
|
-0.121x |
|
Pancontinental Energy NL
AU:PCL
|
-0.064x |
|
Nephros Inc
NASDAQ:NEPH
|
-0.156x |
|
Mabion S.A.
WAR:MAB
|
-0.268x |
Annual Cash Flow Conversion Efficiency for Atara Biotherapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Atara Biotherapeutics Inc from 2012 to 2024. Review free cash flow generation of Atara Biotherapeutics Inc to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-97.28 Million | $-68.72 Million | 0.706x | -63.68% |
| 2023-12-31 | $-99.23 Million | $-192.98 Million | 1.945x | +191.07% |
| 2022-12-31 | $126.64 Million | $-270.43 Million | -2.135x | -170.76% |
| 2021-12-31 | $279.61 Million | $-220.52 Million | -0.789x | -101.72% |
| 2020-12-31 | $462.34 Million | $-180.76 Million | -0.391x | +51.75% |
| 2019-12-31 | $290.78 Million | $-235.63 Million | -0.810x | -52.74% |
| 2018-12-31 | $338.86 Million | $-179.77 Million | -0.531x | -7.84% |
| 2017-12-31 | $177.86 Million | $-87.50 Million | -0.492x | -107.96% |
| 2016-12-31 | $253.74 Million | $-60.02 Million | -0.237x | -100.62% |
| 2015-12-31 | $315.10 Million | $-37.16 Million | -0.118x | +26.83% |
| 2014-12-31 | $103.18 Million | $-16.63 Million | -0.161x | -129.76% |
| 2013-12-31 | $-11.02 Million | $-5.97 Million | 0.542x | -18.45% |
| 2012-12-31 | $-3.73 Million | $-2.48 Million | 0.664x | -- |
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as… Read more